NPCE stock icon

Neuropace

7.51 USD
-0.05
0.66%
At close Nov 8, 4:00 PM EST
1 day
-0.66%
5 days
20.16%
1 month
16.98%
3 months
5.18%
6 months
-40.40%
Year to date
-23.21%
1 year
3.59%
5 years
-69.91%
 

About: NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.

Employees: 179

0
Funds holding %
of 6,759 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

10,600% more call options, than puts

Call options by funds: $214K | Put options by funds: $2K

31% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 13

3.78% less ownership

Funds ownership: 64.67% [Q1] → 60.89% (-3.78%) [Q2]

6% less funds holding

Funds holding: 54 [Q1] → 51 (-3) [Q2]

14% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 21

45% less capital invested

Capital invested by funds: $242M [Q1] → $132M (-$110M) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$15
100%
upside
Avg. target
$16.50
120%
upside
High target
$18
140%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Cantor Fitzgerald
Ross Osborn
55% 1-year accuracy
26 / 47 met price target
140%upside
$18
Overweight
Reiterated
14 Aug 2024
Wells Fargo
Vik Chopra
0% 1-year accuracy
0 / 4 met price target
100%upside
$15
Overweight
Maintained
14 Aug 2024

Financial journalist opinion

Based on 4 articles about NPCE published over the past 30 days

Charts implemented using Lightweight Charts™